CUE icon

Cue Biopharma

0.7851 USD
-0.0715
8.35%
At close Apr 25, 4:00 PM EDT
After hours
0.7850
-0.0001
0.01%
1 day
-8.35%
5 days
3.30%
1 month
-21.18%
3 months
-43.11%
6 months
-46.95%
Year to date
-27.97%
1 year
-44.32%
5 years
-96.82%
10 years
-93.25%
 

About: Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Employees: 41

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

488% more call options, than puts

Call options by funds: $47K | Put options by funds: $8K

280% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 5

50% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 8

22% more capital invested

Capital invested by funds: $10.5M [Q3] → $12.8M (+$2.28M) [Q4]

8% more funds holding

Funds holding: 50 [Q3] → 54 (+4) [Q4]

10.04% less ownership

Funds ownership: 28.6% [Q3] → 18.56% (-10.04%) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$2
155%
upside
Avg. target
$2
155%
upside
High target
$2
155%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Citizens Capital Markets
Reni Benjamin
20% 1-year accuracy
8 / 40 met price target
155%upside
$2
Market Outperform
Reiterated
2 Apr 2025

Financial journalist opinion

Based on 8 articles about CUE published over the past 30 days

Neutral
Seeking Alpha
1 week ago
Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)
Cue Biopharma, Inc. (NASDAQ:CUE ) Business Update Call April 15, 2025 4:30 PM ET Company Participants Eric Ribner - LifeSci Advisors Dan Passeri - Chief Executive Officer Lucinda Warren - Chief Business Officer Operator Good day, and welcome to the Cue Biopharma Business Update Call. All participants are in a listen-only mode.
Cue Biopharma, Inc. (CUE) Business Update Call (Transcript)
Neutral
GlobeNewsWire
1 week ago
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
Ingelheim, Germany, and Boston, MA, USA, April 14, 2025 – Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma's CUE-501 product candidate, a differentiated B cell depletion therapy for autoimmune diseases. Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the potential treatment of autoimmune and inflammatory diseases.
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
Neutral
GlobeNewsWire
1 week ago
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced the pricing of an underwritten public offering of (i) 13,530,780 shares of its common stock and accompanying common stock warrants to purchase an aggregate of 3,382,695 shares of common stock and, (ii) to certain investors in lieu of common stock, pre-funded warrants to purchase 11,469,216 shares of common stock and accompanying common stock warrants to purchase an aggregate of 2,867,304 shares of common stock. Each share of common stock and accompanying common stock warrant are being sold together at a combined public offering price of $0.79, and each pre-funded warrant and accompanying common stock warrant are being sold together at a combined public offering price of $0.789. The aggregate gross proceeds of the offering are expected to be approximately $20 million, before deducting underwriting discounts and commissions and other offering expenses. Each pre-funded warrant will have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until all of the pre-funded warrants are exercised in full. Each common stock warrant will have an exercise price of $0.79 per share, will be exercisable immediately and will expire five years from the date of issuance. The offering is expected to close on or about April 16, 2025, subject to satisfaction of customary closing conditions. All of the securities are being offered by Cue Biopharma.
Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering
Neutral
GlobeNewsWire
1 week ago
Cue Biopharma Announces Proposed Public Offering
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the securities are being offered by Cue Biopharma.
Cue Biopharma Announces Proposed Public Offering
Neutral
GlobeNewsWire
1 week ago
Cue Biopharma to Host Business Update Call and Webcast
BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it will host a conference call and webcast to provide a business update on Tuesday, April 15, 2025 at 4:30 p.m. ET.
Cue Biopharma to Host Business Update Call and Webcast
Neutral
GlobeNewsWire
1 week ago
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
INGELHEIM, Germany and BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma's CUE-501 product candidate, a differentiated B cell depletion therapy for autoimmune diseases. Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the potential treatment of autoimmune and inflammatory diseases.
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
Negative
Zacks Investment Research
3 weeks ago
Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates
Cue Biopharma, Inc. (CUE) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.28 per share a year ago.
Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates
Neutral
GlobeNewsWire
3 weeks ago
Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- - Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today reported fourth quarter and full year 2024 financial results.
Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Neutral
GlobeNewsWire
4 months ago
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced the grant of an inducement option award to its newly appointed interim chief development officer, Daniel Baker, M.D. The grant was approved by a majority of the independent directors of the Company as inducement material to Dr. Baker entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) (“the Inducement Award”).
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neutral
GlobeNewsWire
4 months ago
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced today that it will take part in an unplugged fireside discussion at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY, Dec 3-5, 2024.
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
Charts implemented using Lightweight Charts™